Viewpoint
Lipocortin-1: cellular mechanisms and clinical relevance

https://doi.org/10.1016/0165-6147(94)90281-XGet rights and content

Abstract

Lipocortin-1, a 37 kDa member of the annexin superfamily of proteins, originally evoked interest as one of the ‘second messengers’ of the anti-inflammatory actions of the glucocorticoids. Subsequent research has shown that the protein plays a major regulatory role in systems as diverse as cell-growth regulation and differentiation, neutrophil migration, CNS responses to cytokines, neuroendocrine secretion and neurodegeneration. The role of lipocortin-1 in mediating glucocorticoid-induced effects in these systems has been demonstrated using immunoneutralization strategies and by mimicking steroid actions with highly purified or recombinant lipocortin-1 or its biologically active peptide fragments. Originally the mode of action of lipocortin-1 seemed to be largely through inhibition of prostaglandin formation, but it is now clear that it can modify other aspects of cell function, perhaps pointing to a more fundamental mechanism than was originally envisaged. In this article Rod Flower and Nancy Rothwell review the nature, possible mechanisms and clinical relevance of these diverse actions of lipocortin-1.

References (35)

  • P. Christmas et al.

    J. Biol. Chem.

    (1991)
  • M. Perretti et al.

    Biochem. Biophys. Res. Commun.

    (1993)
  • M.J. Bienkowski et al.

    J. Biol. Chem.

    (1989)
  • E. Solito et al.

    FEBS Lett.

    (1991)
  • N.J. Goulding

    Lancet

    (1990)
  • P.J.L.M. Strijbos et al.

    Brain Res.

    (1991)
  • N.J. Rothwell et al.

    Neurosci. Biobehav. Rev.

    (1993)
  • R.J. Flower

    Br. J. Pharmacol.

    (1988)
  • B.P. Wallner

    Nature

    (1986)
  • R. Fava et al.

    J. Cell. Physiol.

    (1989)
  • J.D. Croxtall et al.
  • N.J. Goulding et al.

    Biochem. Soc. Trans.

    (1990)
  • J.L. Browning et al.
  • S.H. Peers et al.

    Br. J. Pharmacol.

    (1993)
  • B.S. Vishwanath et al.

    Endocrinology

    (1992)
  • M.P. Ambrose et al.

    J. Appl. Physiol.

    (1990)
  • G. Cirino et al.
  • Cited by (336)

    • Glucocorticoids and COVID-19

      2022, Pharmacological Research
      Citation Excerpt :

      The majority of mechanisms involved in the anti-inflammatory activity of GCs are attributed to the direct modulation of gene transcription, including regulation of genes that control cell activation and production of mediators of inflammation [18]. As an example, GCs influence prostaglandin (PG) synthesis, by interaction with GRs, that are transcription factors, and by transcriptional up-regulation of the glucocorticoid-induced leucine zipper (GILZ), and consequently of Annexin-1, which then counters phospholipase A2 (PLA2) activity and arachidonic acid (a precursor in the synthesis of prostanoids) release, a mechanism also involved in GC-regulated apoptosis [31,32]. Moreover, GCs inhibit the cyclooxygenases (COXs) and consequently the metabolism of arachidonic acid [17,33,34].

    • New markers in ulcerative colitis

      2019, Clinica Chimica Acta
    View all citing articles on Scopus
    View full text